These findings indicate that ADAM17 inhibition with TAPI-0 has a positive impact on reducing albumin permeability in glomeruli in diabetic rats, potentially suggesting a promising therapeutic approach to counteract kidney damage in the context of diabetes-related renal complications. Here, ALB is linked to diabetes mellitus.